Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study

被引：0
|
作者：
Gui, L. [1 ]
Chen, X. [2 ]
He, X. [1 ]
Yang, J. [3 ]
Liu, P. [1 ]
Qin, Y. [1 ]
Shi, Y-K. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, CAMS PUMC, Dept Med Oncol, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360MO
引用
收藏
页码：S1609 / S1610
页数：2
相关论文
共 50 条
  • [41] PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)
    Posner, Marshall R.
    Wong, Deborah J. L.
    Harrington, Kevin Joseph
    O'Neal, Richard Lee
    Makris, Lukas
    Perdomini, Morgane
    MacIntyre, Susan
    Denker, Andrew
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
    Tahara, M.
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Burtness, B.
    De Castro, G., Jr.
    Psyrri, A.
    Brana, I.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia Nin, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Gumuscu, B.
    Lerman, N.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S844 - S844
  • [44] A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Pfister, D. G.
    Haque, S.
    Stambuk, H.
    Lisa, D. M.
    Shen, R.
    Carlson, D.
    Fury, M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] PREDICTORS OF EFFICACY IN THE EXTREME STUDY: CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Vermorken, J. B.
    Mesia, R.
    Remenar, E.
    Erfan, J.
    Zabolotnyy, D.
    Benasso, M.
    Koralewski, P.
    Gross, A.
    Stroh, C.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
  • [46] A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Dunn, L. A.
    Fury, M. G.
    Xiao, H.
    Baxi, S. S.
    Sherman, E. J.
    Korte, S.
    Pfister, C.
    Haque, S.
    Katabi, N.
    Ho, A. L.
    Pfister, D. G.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2533 - 2538
  • [47] Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study
    Zhang, Siyi
    Ma, Haiqing
    Zhan, Jiandong
    Zhu, Lijun
    Zhang, Hong-Dan
    Du, Shasha
    Dong, Qiumei
    Wang, Guangyi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study
    Liu, Yizhen
    Xue, Liqiong
    Xia, Zuguang
    Zhang, Qunling
    Guo, Ye
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (09): : 2040 - 2045
  • [49] Real-World Patient Characteristics and Time on Treatment Outcomes Among Patients Receiving First-Line Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States
    Wang, L.
    Black, C.
    Ramakrishnan, K.
    Turzhitsky, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E42 - E42
  • [50] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
    Guigay, J.
    Fayette, J.
    Dillies, A. F.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. P.
    Zanetta, S.
    Pointreau, Y.
    Bozec Le Moal, L.
    Henry, S.
    Schilf, A.
    Bourhis, J.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1941 - 1947
12345